We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

YD DIAGNOSTICS

Specializes in the manufacture of total in vitro diagnostic products. Product applications include urinalysis, blood ... read more Featured Products: More products

Download Mobile App




Semiquantitative Urine Dipstick Evaluated for Microalbuminuria Screening

By LabMedica International staff writers
Posted on 21 Aug 2014
The urine microalbumin test is used as a screening test for the diagnosis of renal complications in diseases, such as diabetic nephropathy, cardiovascular disease, and hypertension.

A urine dipstick test that can conveniently and semiquantitatively measure concentrations of urine microalbumin and creatinine as well as the albumin/creatinine ratio (ACR) has been developed and the diagnostic performance of the dipstick evaluated. More...


Laboratory scientists at the University of Ulsan College of Medicine (Seoul, Republic of Korea) and their colleagues randomly selected 1,040 urine specimens that had been sent for ACR tests from July 1, 2011, to August 31, 2011. Albumin and creatinine tests were performed using random, midstream spot urine samples, and all tests were completed within two hours of urine collection. The results of the dipstick tests were compared with measurements obtained by a quantitative analyzer.

The newly introduced semiquantitative urine dipstick evaluated was the URiSCAN Super cassette ACR (URiSuper-ACR, YD Diagnostics Corp.; Yongin-si, Republic of Korea). Detection of albumin and creatinine in the URiSuper-ACR were performed using the dye-binding and metal complex methods, respectively. The color change made by the reaction was measured by the URiSCAN Super Plus reflectance meter. The Cobas Integra 800 quantitative analyzer (Roche Diagnostics; Rotkreuz Switzerland), which uses immunoturbidometric and the Jaffe-kinetic method, was used as the comparison methodology.

The URiSuper-ACR test showed 88.8% and 86.3% sensitivity and 90.1% and 93.8% specificity for albumin concentration and ACR, respectively and showed 91.1% and 92.6% positive predictive values. The concordance rate between URiSuper-ACR and Cobas Integra quantitative method for albumin and creatinine concentration within the same category were 78.4% and 67.1%, respectively, and for the ±1 category were 98.8% and 99.5%, respectively. For ACR, an 80.0% concordance rate was seen within the same category.

The authors concluded that in their evaluation study on a heterogeneous patient group, the URiSuper-ACR showed good diagnostic performance, such as excellent sensitivity, specificity, concordance rate with quantitative method, linearity, and precision, and this method could be used as an effective screening tool for the detection of microalbuminuria in clinical laboratories. The study was published in the July 2014 issue of the Journal of Clinical Laboratory Analysis.

Related Links:

University of Ulsan College of Medicine
YD Diagnostics Corp. 
Roche Diagnostics



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.